Frontlight ResearchEarly access
CompletedNo phase
Microneedling-Assisted Delivery of Cetirizine Versus Latanoprost in Alopecia Areata
Key facts
- Who runs it
- Tanta University
- Where
- Egypt1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 80 people enrolled
- Started
- 1 Oct 2022
- Ended
- 1 Oct 2024
- Type of study
- Interventional, 4 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Cetirizine (Zyrtec)
- Latanoprost
- Triamcinolone Acetonide
- Microneedling only
- Record updated
- 11 August 2026
Who can take part
- Sex
- Women and men
- Healthy volunteers
- Can take part
The registry criteria, word for word
Show all 13 criteriaShow less
Who can take part
- Newly diagnosed cases of alopecia areata
- Patients of any age
- Both male and female patients
- Recent-onset patchy alopecia areata of ≤6 months' duration
- Presence of no more than two alopecia patches
- Stationary course of the disease
- Willingness to participate in the study
- Provision of written informed consent or parental/guardian consent for minors
Who cannot take part
- Previous treatment of the alopecia areata lesions
- Active scalp infection
- Presence of associated dermatological, systemic, or autoimmune comorbidities
- Known allergy or hypersensitivity to any of the planned therapeutic agents
- Extensive alopecia areata, including alopecia totalis or alopecia universalis
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This study planned to measure the effectiveness and safety of microneedling aided administration of cetirizine 1% versus latanoprost 0.01% in alopecia areata.
The 4 groups in the trial
- Group ATreatment being tested
Patients treated with microneedling-aided administration of topical cetirizine 1% solution.
Treatment: Cetirizine (Zyrtec)
- Group BTreatment being tested
Patients treated with microneedling-aided administration of topical latanoprost 0.01% solution.
Treatment: Latanoprost
- group CExisting treatment, for comparison
Patients treated with microneedling-aided administration of topical triamcinolone acetonide (TrA) (10mg/ml) as a positive control group
Treatment: Triamcinolone Acetonide
- Group DExisting treatment, for comparison
Patients treated with microneedling only as a negative control group
Treatment: Microneedling only
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Microneedling-Assisted Delivery of Cetirizine Versus Latanoprost in Alopecia Areata: A Pilot Randomized Controlled Study
- Record updated
- 11 August 2026